1. miRNA-22 as a Candidate Diagnostic Biomarker for Coronary Slow Flow
- Author
-
Chuan-Chang Li, Tong Chen, and Zhen-Yu Wang
- Subjects
medicine.medical_specialty ,Article Subject ,Receiver operating characteristic ,business.industry ,Context (language use) ,Disease ,030204 cardiovascular system & hematology ,medicine.disease ,Slow Flow ,Gastroenterology ,Confidence interval ,03 medical and health sciences ,Stenosis ,0302 clinical medicine ,RC666-701 ,030220 oncology & carcinogenesis ,Internal medicine ,microRNA ,medicine ,Diseases of the circulatory (Cardiovascular) system ,Diagnostic biomarker ,Cardiology and Cardiovascular Medicine ,business ,Research Article - Abstract
Background. Coronary slow flow (CSF) refers to the phenomenon of delayed distal flow in the absence of lesions detected on coronary angiography. Although the detection rate of CSF has been increasing in clinical practice, early diagnosis is difficult and the factors contributing to this condition remain unclear. Given the increasing demonstration of the roles of microRNAs (miRNAs) in disease and as diagnostic biomarkers, the aim of this study was to analyze the expression of serum miRNA-22 in patients with CSF detected using coronary angiography and its diagnostic efficacy. Methods and Results. A retrospective analysis including 44 patients with CSF and 42 patients with normal coronary flow (control group) was conducted. Additionally, all included patients either did not have visually estimated coronary artery stenosis or had Results. The expression of serum miRNA-22 was significantly higher in the CSF patients than in the control subjects (P Conclusions. The expression of serum miRNA-22 in CSF is upregulated compared to that in subjects with normal coronary flow and shows relatively high clinical diagnostic efficiency, suggesting a new potential biomarker for the early diagnosis of CSF.
- Published
- 2020
- Full Text
- View/download PDF